• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

奥希替尼成功治疗伴有表皮生长因子受体（EGFR）T790M突变的肺腺癌软脑膜癌病。

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR.

作者信息

Sakai Hitomi, Hayashi Hidetoshi, Iwasa Tsutomu, Hasegawa Yoshikazu, Takeda Masayuki, Nakagawa Kazuhiko

机构信息

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama,Japan.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama,Japan.

出版信息

ESMO Open. 2017 Mar 7;2(Suppl 1):e000104. doi: 10.1136/esmoopen-2016-000104. eCollection 2017.

DOI:10.1136/esmoopen-2016-000104
PMID:28848674
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5559906/
Abstract

Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that has been approved for the treatment of metastatic non-small cell lung cancer (NSCLC) positive for the secondary T790M mutation of EGFR. In a preclinical study, it also showed efficacy against leptomeningeal carcinomatosis (LMC) derived from NSCLC resistant to first-generation and second-generation EGFR-TKIs. We now report the case of a patient aged 70 years with symptomatic LMC derived from NSCLC with the T790M mutation of EGFR who showed a clinical and radiographic response to osimertinib.

摘要

奥希替尼是一种表皮生长因子受体（EGFR）的第三代酪氨酸激酶抑制剂（TKI），已被批准用于治疗EGFR继发性T790M突变阳性的转移性非小细胞肺癌（NSCLC）。在一项临床前研究中，它还显示出对源自对第一代和第二代EGFR-TKIs耐药的NSCLC的软脑膜癌病（LMC）有效。我们现在报告一例70岁的患者，其患有源自NSCLC且具有EGFR T790M突变的有症状LMC，该患者对奥希替尼表现出临床和影像学反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9fc/5559906/b5c622cb65bb/esmoopen-2016-000104f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9fc/5559906/b5c622cb65bb/esmoopen-2016-000104f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9fc/5559906/b5c622cb65bb/esmoopen-2016-000104f01.jpg

相似文献

1
Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR.奥希替尼成功治疗伴有表皮生长因子受体（EGFR）T790M突变的肺腺癌软脑膜癌病。
ESMO Open. 2017 Mar 7;2(Suppl 1):e000104. doi: 10.1136/esmoopen-2016-000104. eCollection 2017.
2
Osimertinib in the treatment of leptomeningeal disease in T790M-negative, epidermal growth factor receptor-mutated non-small cell lung cancer: a case report.奥希替尼治疗T790M阴性、表皮生长因子受体突变的非小细胞肺癌脑膜转移：一例报告
Chin Clin Oncol. 2019 Jun;8(3):29. doi: 10.21037/cco.2019.02.02. Epub 2019 Mar 4.
3
Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.奥希替尼诱发间质性肺病后使用阿美替尼成功治疗EGFR T790M突变型非小细胞肺癌：一例报告及文献综述
Ann Transl Med. 2021 Jun;9(11):950. doi: 10.21037/atm-21-2823.
4
Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of -mutant Lung Cancer.拷贝数增加与EGFR突变型肺癌软脑膜转移瘤对吉非替尼耐药相关。
Mol Cancer Ther. 2017 Mar;16(3):506-515. doi: 10.1158/1535-7163.MCT-16-0522. Epub 2017 Jan 30.
5
Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).表皮生长因子受体T790M突变阳性的转移性非小细胞肺癌：聚焦奥希替尼（AZD9291）
Onco Targets Ther. 2017 Mar 22;10:1757-1766. doi: 10.2147/OTT.S100650. eCollection 2017.
6
Leptomeningeal Metastatic L858R -mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib.软脑膜转移的L858R突变型肺癌：在无T790M突变情况下对奥希替尼迅速起效及后续脉冲式厄洛替尼治疗有效
Onco Targets Ther. 2022 Jun 14;15:659-667. doi: 10.2147/OTT.S336012. eCollection 2022.
7
Standard dose osimertinib for erlotinib refractory T790M-negative -mutant non-small cell lung cancer with leptomeningeal disease.标准剂量奥希替尼用于治疗对厄洛替尼耐药的T790M阴性突变非小细胞肺癌伴软脑膜疾病。
J Thorac Dis. 2019 May;11(5):1756-1764. doi: 10.21037/jtd.2019.05.41.
8
Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?我们能否确定表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体突变的非小细胞肺癌的最佳用药顺序？
Curr Opin Oncol. 2017 Mar;29(2):89-96. doi: 10.1097/CCO.0000000000000350.
9
Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.表皮生长因子受体（EGFR）突变阳性非小细胞肺癌患者一线 EGFR 酪氨酸激酶抑制剂治疗后治疗模式的观察性研究。
Adv Ther. 2020 Feb;37(2):946-954. doi: 10.1007/s12325-020-01221-4. Epub 2020 Jan 18.
10
A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.AME肺癌协作组关于奥希替尼在非小细胞肺癌中作用的共识。
J Thorac Dis. 2018 Jul;10(7):3909-3921. doi: 10.21037/jtd.2018.07.61.

引用本文的文献

1
Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysiss.奥希替尼与经治的非小细胞肺癌软脑膜转移患者预后改善相关：一项系统评价和荟萃分析。
Heliyon. 2024 Apr 17;10(9):e29668. doi: 10.1016/j.heliyon.2024.e29668. eCollection 2024 May 15.
2
The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review.脑放疗在 EGFR 和 ALK 阳性非小细胞肺癌伴脑转移中的作用：综述。
Radiol Med. 2023 Mar;128(3):316-329. doi: 10.1007/s11547-023-01602-z. Epub 2023 Feb 14.
3
First-line osimertinib for leptomeningeal metastasis from lung adenocarcinoma with mutation as the initial and solitary site of postoperative recurrence.

本文引用的文献

1
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.在 EGFR 突变型 NSCLC 脑转移模型中奥希替尼与其他 EGFR-TKIs 的临床前比较，以及临床脑转移活性的早期证据。
Clin Cancer Res. 2016 Oct 15;22(20):5130-5140. doi: 10.1158/1078-0432.CCR-16-0399. Epub 2016 Jul 19.
2
High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells.第三代表皮生长因子受体（EGFR）抑制剂AZD9291在伴有EGFR突变肺癌细胞的软脑膜癌病模型中具有高效性。
Oncotarget. 2016 Jan 26;7(4):3847-56. doi: 10.18632/oncotarget.6758.
3
一线使用奥希替尼治疗肺腺癌软脑膜转移，该转移作为术后复发的初始及唯一部位且存在 突变。 （注：原文中“ mutation”处信息缺失）
Int Cancer Conf J. 2020 Oct 16;10(1):78-82. doi: 10.1007/s13691-020-00453-z. eCollection 2021 Jan.
4
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.非小细胞肺癌脑转移的治疗。
Int J Mol Sci. 2021 Jan 8;22(2):593. doi: 10.3390/ijms22020593.
5
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.奥希替尼治疗表皮生长因子受体突变阳性非小细胞肺癌伴脑膜转移患者：BLOOM 研究。
J Clin Oncol. 2020 Feb 20;38(6):538-547. doi: 10.1200/JCO.19.00457. Epub 2019 Dec 6.
6
Current views on molecularly targeted therapy for lung cancer - a review of literature from the last five years.肺癌分子靶向治疗的当前观点——对过去五年文献的综述
Kardiochir Torakochirurgia Pol. 2018 Jun;15(2):119-124. doi: 10.5114/kitp.2018.76478. Epub 2018 Jun 25.
7
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌中枢神经系统转移。
Oncologist. 2018 Oct;23(10):1199-1209. doi: 10.1634/theoncologist.2017-0572. Epub 2018 Apr 12.
8
Efficacy of osimertinib in a patient with non-small cell lung cancer harboring epithelial growth factor receptor exon 19 deletion/T790M mutation, with poor performance status.奥希替尼对一名患有上皮生长因子受体外显子19缺失/T790M突变、体能状态较差的非小细胞肺癌患者的疗效。
Mol Clin Oncol. 2018 Feb;8(2):246-249. doi: 10.3892/mco.2017.1522. Epub 2017 Nov 29.
9
Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation.携带EGFR T790M突变的非小细胞肺癌患者软脑膜转移的治疗
Case Rep Oncol. 2017 Sep 20;10(3):840-845. doi: 10.1159/000480452. eCollection 2017 Sep-Dec.
Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI.
EGFR-TKI 获得性耐药后个体 EGFR 突变型非小细胞肺癌患者中 T790M 的时空异质性。
J Thorac Oncol. 2015 Nov;10(11):1553-9. doi: 10.1097/JTO.0000000000000647.
4
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.阿法替尼治疗表皮生长因子受体抑制剂耐药的非小细胞肺癌
N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.
5
Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.厄洛替尼对比吉非替尼用于非小细胞肺癌脑膜转移的控制。
J Thorac Oncol. 2013 Aug;8(8):1069-74. doi: 10.1097/JTO.0b013e318294c8e8.
6
Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.非小细胞肺癌患者的脑膜转移癌：对生存的影响及相关预后因素。
J Thorac Oncol. 2013 Feb;8(2):185-91. doi: 10.1097/JTO.0b013e3182773f21.
7
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.吉非替尼治疗初治肺腺癌脑及软脑膜转移的疗效观察
J Thorac Oncol. 2009 Nov;4(11):1415-9. doi: 10.1097/JTO.0b013e3181b62572.
8
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.对于携带表皮生长因子受体突变且无化疗指征的晚期非小细胞肺癌患者，一线使用吉非替尼。
J Clin Oncol. 2009 Mar 20;27(9):1394-400. doi: 10.1200/JCO.2008.18.7658. Epub 2009 Feb 17.
9
Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma.肺腺癌中软脑膜和脊髓对二线厄洛替尼的反应
J Thorac Oncol. 2008 Jun;3(6):677-9. doi: 10.1097/JTO.0b013e3181757a8b.
10
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.非小细胞肺癌患者表皮生长因子受体基因突变及对吉非替尼获得性耐药的分析
Clin Cancer Res. 2006 Oct 1;12(19):5764-9. doi: 10.1158/1078-0432.CCR-06-0714.